Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker (2022)
- Authors:
- Araujo, Rogerio Agenor de
- Monteiro, Maria Luíza Gonçalves dos Reis
- Bernardino Neto, Morun
- Silva, Marcelo José Barbosa
- LUZ, Felipe Andrés Cordero da
- Marinho, Eduarda da Costa
- Nascimento, Camila Piqui
- Marques, Lara de Andrade
- Delfino, Patrícia Ferreira Ribeiro
- Antonioli, Rafael Mathias
- Araújo, Breno Jeha
- Silva, Ana Cristina Araújo Lemos da
- Araujo, Rogerio Agenor de
- Autor USP: BERNARDINO NETO, MORUN - EEL
- Unidade: EEL
- DOI: 10.3332/ecancer.2022.1431
- Subjects: PROGNÓSTICO; NEOPLASIAS
- Keywords: tEGFR; sEGFR; breast cancer; prognosis
- Language: Inglês
- Abstract: Background: Epidermal growth factor receptor (EGFR) overexpression has been considered a poor prognostic factor in breast cancer. Methodology: A prospective study of 206 women with breast cancer analysed by stages (I, II, III and IV) and by immunohistochemical subtype (Luminal A, Luminal B, HER2+ and triple-negative (TN)); 89 healthy controls with normal recent mammography were included. The EGFR measured in the serum (sEGFR) was detected by the Enzyme-Linked Immunosorbent Assay (ELISA) method (R&D Systems kit DY231) collected by blood before any treatment in patients. Kaplan–Meier method and Cox regression were carried out to obtain the prognostic value, considering significance if p < 0.05. Results: With a median follow-up of 36.6 months, 47 deaths occurred. Multivariable Cox regression showed difference of overall survival (OS) associated with sEGFR levels (sEGFR ≤ or > 47.8 ng/mL) in patients with TN cancers, but not of Luminal A, Luminal B or HER2+ subtypes; adjusted by stage, the death risk increased by approximately 415% [hazard ratio (HR): 5.149 (1.900–13.955), p = 0.001] for patients with sEGFR > 47.8 ng/mL compared to patients with a lower sEGFR value. There was no significant correlation of sEGFR with staging, histological tumour grade (G1/G2/G3), Ki67 (< or ≥14%) or body mass index. Conclusions: Increased sEGFR expression in patients with TN tumours is a significant predictor of lower OS and its quantification is inexpensive and straightforward.
- Imprenta:
- Source:
- Título: Ecancermedicalscience
- ISSN: 17546605
- Volume/Número/Paginação/Ano: v.16, n. 1431, p.1-16, 2022
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
ARAUJO, Rogerio Agenor de et al. Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker. Ecancermedicalscience, v. 16, n. 1431, p. 1-16, 2022Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2022.1431. Acesso em: 28 fev. 2026. -
APA
Araujo, R. A. de, Monteiro, M. L. G. dos R., Bernardino Neto, M., Silva, M. J. B., LUZ, F. A. C. da, Marinho, E. da C., et al. (2022). Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker. Ecancermedicalscience, 16( 1431), 1-16. doi:10.3332/ecancer.2022.1431 -
NLM
Araujo RA de, Monteiro MLG dos R, Bernardino Neto M, Silva MJB, LUZ FAC da, Marinho E da C, Nascimento CP, Marques L de A, Delfino PFR, Antonioli RM, Araújo BJ, Silva ACAL da. Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker [Internet]. Ecancermedicalscience. 2022 ;16( 1431): 1-16.[citado 2026 fev. 28 ] Available from: https://doi.org/10.3332/ecancer.2022.1431 -
Vancouver
Araujo RA de, Monteiro MLG dos R, Bernardino Neto M, Silva MJB, LUZ FAC da, Marinho E da C, Nascimento CP, Marques L de A, Delfino PFR, Antonioli RM, Araújo BJ, Silva ACAL da. Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker [Internet]. Ecancermedicalscience. 2022 ;16( 1431): 1-16.[citado 2026 fev. 28 ] Available from: https://doi.org/10.3332/ecancer.2022.1431 - EGF (epidermal growth factor) receptor expression in blood: Prognostic biomarker in overall survival (OS) of patients with non-metastatic triple negative (TN) breast carcinoma.
- Influence of erythrocyte membrane stability in atherosclerosis
- Swimming reduces fatty acids-associated hypothalamic damage in mice
- The elusive Luminal B breast cancer and the mysterious chemokines
- Correlations of the glycemic variability with oxidative stress and erythrocytes membrane stability in patients with type 1 diabetes under intensive treatment
- How effective is the use of glycemic variability in the follow-up of type 1 diabetes under intensive care?
- Expression of epidermal growth factor receptor (EGFR) in blood and tumor in patients with breast carcinoma: Prognostic analysis.
- Aging profile, adherence to the Elderly Health Handbook and health self-perception, Ituiutaba-MG (2015 and 2018)
- Saúde Mental, Uso de Álcool e Qualidade do Sono em Estudantes de uma Universidade Pública
- Oropharyngeal Colostrum Administration and Anti-inflammatory Effects in Very Low Birth Weight Preterm Neonates
Informações sobre o DOI: 10.3332/ecancer.2022.1431 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
